Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HELENA
- Sponsors Roche
- 05 Dec 2018 Planned End Date changed from 15 Dec 2020 to 29 Feb 2020.
- 05 Dec 2018 Planned primary completion date changed from 15 Dec 2020 to 29 Feb 2020.
- 21 Mar 2017 Planned End Date changed from 1 Sep 2017 to 15 Dec 2020.